MU-D201
Innovative agent inhibits TGF-β signaling
and epigenetic mechanisms in cancer
First Discovery of DRAK2 Target Protein
- When DRAK2 is overexpressed in cancer tissues, it inhibits the inhibitory activity of TGF-β to promote cancer growth and metastasis
Drug Development Roadmap
-
Small Molecule Compound
MU-D201
-
Biomarker
EZH2 gene mutation, gamma delta (γδ) T-cell receptor mutation
Fast track commercial approval expected for treatment of rare diseases
- (Diffuse large B-cell lymphoma which is characterized by EZH2 gene mutations and gamma delta (γδ) T-cell leukemia)
Diffuse large B-cell lymphoma
DRAK2 is overexpressed in diffuse giant B cell lymphoma cells with EZH2 gene mutation.
Gamma delta (γδ) T-cell leukemia
DRAK2 inhibitor MU-D201 induces apoptosis in gamma delta T cell lymphoid leukemia cells
